3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Cancer, Papillary
1
Solitary Fibrous Tumors
1
Sarcoma
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Interventions
Cisplatin
281
pembrolizumab
234
Radiotherapy
171
Cetuximab
169
Carboplatin
123
Docetaxel
110
Paclitaxel
96
Fluorouracil
95
Nivolumab
88
Radiotherapy, Intensity-Modulated
80
Magnetic Resonance Spectroscopy
39
durvalumab
36
Radiation
33
Surgical Procedures, Operative
32
Drug Therapy
32
Biopsy
28
Radiosurgery
25
Erlotinib Hydrochloride
25
Albumin-Bound Paclitaxel
24
130-nm albumin-bound paclitaxel
24
Taxes
23
Specimen Handling
22
Platinum
22
Immunohistochemistry
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Cyclophosphamide
19
Chemoradiotherapy
19
Capecitabine
19
tremelimumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Famotidine
×
Head & Neck
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled
NCT03107182
2025-05-06
OPTIMA-II
University of Chicago
Phase 2
Completed
72 enrolled
14 charts